These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 29248177)

  • 41. Modeling falls in Parkinson's disease: Slow gait, freezing episodes and falls in rats with extensive striatal dopamine loss.
    Kucinski A; Albin RL; Lustig C; Sarter M
    Behav Brain Res; 2015 Apr; 282():155-64. PubMed ID: 25595423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease.
    Jadiya P; Chatterjee M; Sammi SR; Kaur S; Palit G; Nazir A
    Biochem Biophys Res Commun; 2011 Sep; 413(2):306-10. PubMed ID: 21889494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.
    Voutilainen MH; Arumäe U; Airavaara M; Saarma M
    FEBS Lett; 2015 Dec; 589(24 Pt A):3739-48. PubMed ID: 26450777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parafoveal Change and Dopamine Loss in the Retina with Parkinson's Disease.
    Lee JY; Ahn J; Shin JY; Jeon B
    Ann Neurol; 2021 Feb; 89(2):421-422. PubMed ID: 33236378
    [No Abstract]   [Full Text] [Related]  

  • 47. Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Kulikovskaja L; Seibler P
    Mov Disord; 2018 Feb; 33(2):250. PubMed ID: 29168581
    [No Abstract]   [Full Text] [Related]  

  • 48. Increased O-GlcNAcylation prevents degeneration of dopamine neurons.
    Hart GW; Huang CW
    Brain; 2020 Dec; 143(12):3515-3518. PubMed ID: 33439984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. α-Synuclein and Tau: Mitochondrial Kill Switches.
    Pech U; Verstreken P
    Neuron; 2018 Jan; 97(1):3-4. PubMed ID: 29301103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Innate Immunity in Mucopolysaccharide Diseases.
    Mandolfo O; Parker H; Bigger B
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216110
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Peek into Parkinson's Disease Progression through Human Dopamine Neurons in a Dish.
    Yang N; Yue Z
    Trends Neurosci; 2018 Feb; 41(2):74-76. PubMed ID: 29248177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
    Duda J; Pötschke C; Liss B
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
    Bisaglia M; Filograna R; Beltramini M; Bubacco L
    Ageing Res Rev; 2014 Jan; 13():107-14. PubMed ID: 24389159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies.
    Bisaglia M; Greggio E; Beltramini M; Bubacco L
    FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.